Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model

被引:17
作者
Maronpot, RR
Mitsumori, K
Mann, P
Takaoka, M
Yamamoto, S
Usui, T
Okamiya, H
Nishikawa, S
Nomura, T
机构
[1] NIEHS, Lab Expt Pathol, Res Triangle Pk, NC 27709 USA
[2] Natl Inst Hlth Sci, Tokyo 158, Japan
[3] Expt Pathol Labs, Res Triangle Pk, NC USA
[4] Sankyo Co, Shizuoka, Japan
[5] Keio Univ, Sch Med, Tokyo, Japan
[6] Cent Inst Expt Anim, Kawasaki, Kanagawa, Japan
[7] Yamanouchi Pharmaceut Co Ltd, Tokyo, Japan
[8] Kyowa Hakko Kogyo Co Ltd, Ube, Yamaguchi, Japan
关键词
cancer bioassays; animal models; carcinogenicity; transgenic mice; hazard identification;
D O I
10.1016/S0300-483X(00)00168-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Several genetically engineered mouse models are currently being examined for potential use in cancer hazard identification. We have undertaken an interlaboratory comparison of the performance of the CB6F1-Tg rasH2 transgenic mouse in cancer bioassays concurrently conducted in the United States and Japan. Chemicals selected for study included known human carcinogens (melphalan and cyclosporin A) and known rodent carcinogens (p-cresidine and vinyl carbamate) tested at carcinogenic doses, and non-carcinogens (p-anisidine and resorcinol) tested at appropriate high doses. Because of abdominal adhesions caused by the intraperitoneal dosing vehicle, melphalan was excluded from the study results. The remaining five studies showed similar results between the two laboratories conducting each study. Vinyl carbamate gave the strongest positive response inducing lung adenomas and carcinomas and splenic hemangiosarcomas. p-Cresidine was considered positive for urinary bladder transitional neoplasia, Cyclosporin A, p-anisidine, and resorcinol were negative in all studies. Although only five chemicals were successfully tested in this interlaboratory comparison, there was good concordance in outcome for the strong carcinogens and for the non-carcinogens. Successful testing of chemicals with less carcinogenic potential may require modifications in study design to include more animals and longer study duration. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 159
页数:11
相关论文
共 19 条
  • [1] ANDO K, 1992, CANCER RES, V52, P978
  • [2] DAHL GA, 1978, CANCER RES, V38, P3793
  • [3] DOI ST, 1994, JPN J CANCER RES, V85, P801, DOI 10.1111/j.1349-7006.1994.tb02951.x
  • [4] The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens
    Eastin, WC
    Haseman, JK
    Mahler, JF
    Bucher, JR
    [J]. TOXICOLOGIC PATHOLOGY, 1998, 26 (04) : 461 - 473
  • [5] GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.2307/2334765
  • [6] *INT COORD COMM VA, 1997, NIH PUBL NAT I ENV H
  • [7] Lehmann E. L., 1975, NONPARAMETRICS STAT
  • [8] MASSEY TE, 1995, P SOC EXP BIOL MED, V208, P213, DOI 10.3181/00379727-208-43852A
  • [9] Mitsumori K, 1997, MOL CARCINOGEN, V20, P298, DOI 10.1002/(SICI)1098-2744(199711)20:3<298::AID-MC6>3.0.CO
  • [10] 2-H